Marker Therapeutics, Inc.

US venture capital investment in pharmaceutical and biotechnology companies rose from $9.7bn in the first half of 2018 to $14.5bn through the third quarter, beating by a wide margin the $11.9bn raised

Investors can't get enough of companies that are developing drugs to treat non-alcoholic steatohepatitis (NASH), more than doubling the value of two small biopharmaceutical firms based on recent mid-s

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer